Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.